摘要
目的:通过对58例宫颈癌患进行病理分析,总结宫颈癌的病理特点,为临床诊治疾病提供可靠的参考依据,提高患者的生存率。方法:回顾性分析58例宫颈癌患者的临床资料,病理诊断采用WHO子宫体肿瘤组织分类(2003)标准。将全部病人按年龄划分为对照组和研究组,>35岁者为对照组(46例),≤35岁者为研究组(12例)。结果:2组鳞癌共计49例,占全部患者的84.5%(49/58),腺癌共计8例,占13.8%(8/58)。对照组≤Ⅱa期37例(80.4%),≥Ⅱb期7例(15.2%)。研究组≤Ⅱa期11例(91.7%),≥Ⅱb期1例(8.3%);2组分期差异有统计学意义(P≥0.05)。结论:宫颈癌主要分为鳞癌和腺癌2类,组织学诊断是宫颈病变诊断的金标准。临床临床分期越早,越有利于治疗方法的选择,患者的生活质量也将大大提高。
Objective:To summarizes the pathological features of cervical cancer , provide reliable reference to the clinical diagnosis and treatment of relevant diseases , and thus help to improve the survival rate of patient through the pathological analysis of the 58 cases of cervical cancer patients .Methods:A retrospective analysis was carried out among 58 cases of cervical cancer patients with clinical data . The standard of WHO uterine tumor classification was adopted for pathological diagnosis .All patients were divided into control group and research group according to their ages , respectively, patients below 35 years of age were in the control group (46 cases), and patients 35 years old and above were in the research group (12 cases).Results:There were a total of 49 cases of squamous carcinoma , accounting for 84.5%of all patients (49/58);there were a total of eight cases of adenomatous carcinoma , accounting for 13.8%(8/58).In the con-trol group, 37 cases (80.4%)≤stage II a, and 7 cases (15.2%)≥stageⅡb.In the research group , 11 cases (91.7%)≤stageⅡa, 1 case (8.3%)≥stage Ⅱb;the staging difference of the two groups was statistically significant (P≥0.05).Conclusion:Cervical cancer would be mainly divided into two types , namely, squamous carcinoma and adenomatous carcinoma .Histological diagnosis should be the gold standard for the diagnosis of cervical lesions .The sooner clinical staging would be conducted , the better the treatment be se-lected, and the more the patients'life quality is promoted .
出处
《中国伤残医学》
2014年第2期10-12,共3页
Chinese Journal of Trauma and Disability Medicine
关键词
子宫颈癌
病理诊断
临床分期
宫颈疾病筛查
Cervical cancer
Pathological diagnosis
Clinical staging
Cervical disease screening